Fronteo: Report on Corporate Governance, July 3, 2024.
Fronteo: Interim report
Fronteo: Fronteo Legal Report (spring 2024) published, more than half of the respondents answered that they have experienced dealing with emergencies (fraud/misconduct).
Fronteo: Confirmatory letter.
Fronteo: Internal Control Report - 21st Period (April 1, 2023 - March 31, 2024)
Fronteo: Financial Report - Term 21 (2023/04/01 - 2024/03/31)
Fronteo: FRONTEO's Compliance Audit AI Solution has been introduced by over 30 companies, including major financial institutions.
Fronteo: Matters related to business plans and growth potential.
Fronteo: Holding the FRONTEO AI Innovation Forum 2024.
Fronteo: The 21st regular shareholders' meeting material (omission of written deliverables)
Fronteo: Notice of the 21st Regular Shareholders' Meeting and Shareholders' Meeting Materials (Distributed Documents)
Fronteo: Medical paper search AI system “KIBIT Amanogawa” introduced at Asuka Pharmaceutical Co., Ltd.
Fronteo: Notice Concerning Decrease in Amount of Capital and Capital Reserve and Disposal of Surplus Funds
Fronteo: Acquired patent assessments in the US for unique technologies that solve natural language processing issues such as LLM
Fronteo: A new function to present a list of genes and diseases with high similarity and relatedness has been added to the medical paper search AI system “KIBIT Amanogawa”
Fronteo: A new function showing companies subject to the OFAC 50% rule has been added to the economic security AI solution “KIBIT Seizu Analysis”
Fronteo: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Fronteo: FRONTEO, Shionogi Pharmaceutical, and Suzuken aim for social implementation of an AI program to support conversational dementia diagnosis through collaboration between 3 companies
Fronteo: Extraordinary Report
Fronteo: Notice regarding the recording of extraordinary losses (consolidated/individual) and revisions to consolidated earnings forecasts
No Data